There are no upcoming events at this time.

View All
View Full Calendar See All Updates

Get Email Updates

Letter

Letter to HHS Regarding State-Run Health Care Exchanges

06.03.14

Excerpt: While much attention has been paid to the technological challenges encountered by HealthCare.gov and the Federally Facilitated Marketplace (FFM), many exchanges built by states have encountered serious problems as well.

To read the letter, click here. 

To read a related press release, click here. 

Subcommittees
Health (113th Congress)
Health
Letter

Energy and Commerce Committee

Related News


Letters to Pharmacy Benefit Mangers Regarding their Role in the Drug Supply Chain

08.30.2018

Excerpt: “Today, PBMs manage prescription drug benefits on behalf of a wide array of entities – employer-sponsored health plans, health maintenance organizations, Medicaid managed care plans, and Medicare Part D plans. In fact, a February 2016 report estimated PBMs serve 266 million Americans—most of whom are enrolled in private health plans—and can save plan sponsors significant money on drug benefit costs using a wide range of tools. This study also estimated that the use of these tools will save a total of $654 billion across plan sponsors and members, Medicare...

Letter

Letter to MedPAC Requesting Research on Hospital Consolidation and Impact on Patients

08.30.2018

Excerpt: “Through its public hearings, the committee has heard differing views from experts on the extent to which consolidation is a cost driver in the Medicare program and the degree to which payment policies of the Medicare program encourage such consolidation. Some have questioned the merit of concerns over consolidation and have instead highlighted the beneficial efficiencies and economies of scale that can be accomplished through consolidation. For example, in testimony before the Energy and Commerce Health Subcommittee on May 21, 2014, during a hearing entitled ‘Keeping the Promise: Site-of-Service...

Letter

Letter to HRSA Urging Effective Administration of the 340B Drug Pricing Program

08.27.2018

Excerpt: “Given the important role the 340B Program plays in our nation’s health care safety-net, it is critical that program rules be clear and consistent for all stakeholders. Unfortunately, the agency has faced significant impediments to appropriate oversight and enforcement given recent judicial decisions that, in effect, left the agency without broad rulemaking authority.”

To read a copy of the letter, click here.

Letter